# Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects

> **NCT02202473** · PHASE4 · COMPLETED · sponsor: **Southeast University, China** · enrollment: 192 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Lamivudine
- **DRUG:** Lamivudine+Oxymatrine Capsules

## Key facts

- **NCT ID:** NCT02202473
- **Lead sponsor:** Southeast University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2014-02
- **Final completion:** —
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2014-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02202473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02202473, "Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02202473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*